Skip to main content

Table 3 Acute adverse events (AEs) during neoadjuvant therapy in Group C and Group D

From: Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center

  Group C (n = 170) Group D (n = 98)
Grade 1–2 (%) Grade 3–4 (%) Grade 1–2 (%) Grade 3–4 (%)
Leukopenia 107 (62.9) 16 (9.4) 57 (58.2) 8 (8.2)
Neutropenia 76 (44.7) 19 (11.2) 42 (42.9) 13 (13.3)
Anemia 63 (37.1) 6 (3.5) 34 (34.7) 5 (5.1)
Thrombocytopenia 31 (18.2) 2 (1.2) 22 (22.4) 0 (0.0)
Radiation proctitis 96 (56.5) 0 (0.0) 36 (36.7) 0 (0.0)